Checkmate Pharmaceuticals has a market capitalisation of US$119m and burnt through US$44m last year, which is 37% of the company's market value. That's not insignificant, ...

CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its ...

RENSSELAER - Regeneron Pharmaceuticals Inc. is moving to acquire Checkmate Pharmaceuticals in a $250 million all-cash purchase this year. Regeneron said it reached a "definitive" agreement with ...

CAMBRIDGE, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its ...

Checkmate Pharmaceuticals, a clinical stage immuno-oncology biotech developing therapies for solid tumors, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $75 ...

CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its ...

As of December 31st, 2020, Checkmate Pharmaceuticals had cash, cash equivalents, and investments of roughly $125 million. Research and development expenses for the year were $26.7 million ...

Alan Fuhrman, experienced biotech executive and Checkmate board member, appointed as interim President and CEOCAMBRIDGE, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc ...

Checkmate Pharmaceuticals Inc (NASDAQ: CMPI) shares are trading higher by 328.40% to $10.41 during Tuesday's pre-market session after Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced a deal ...